Previous close | 107.66 |
Open | 107.00 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 108.57 - 108.65 |
52-week range | 93.36 - 115.80 |
Volume | |
Avg. volume | 83,783 |
Market cap | N/A |
Beta (5Y monthly) | 0.75 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 18 Jul 2024 - 22 Jul 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Investors need to pay close attention to Abbot Laboratories (ABT) stock based on the movements in the options market lately.
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.
Key Insights Abbott Laboratories to hold its Annual General Meeting on 26th of April Total pay for CEO Robert Ford...